Pharmaceutical companies remain focused on developing highly efficacious therapies with minimal adverse effects. The deepening molecular understanding of diseases—including complex signaling pathways, crosstalk mechanisms, and gene-environment interactions—has paved the way for targeted and transformative treatments.  Recent years have seen the rise of AI-driven drug discovery, organ-on-a-chip models, and multi-omics data integration. These advances, alongside innovations in delivery systems, biodegradable polymers, diagnostic tools, and device-enabled therapeutics, have significantly accelerated translational research. As a result, the pipeline of precision medicines and combination therapies continues to grow across diverse therapeutic areas.

Identifying therapeutic targets remains a cornerstone in the development of safe and effective treatments. While initial monotherapies are designed to address specific patient subpopulations—a defining feature of personalized medicine—advancing biological research continues to expand their utility through synergistic drug combinations. In oncology, groundbreaking advances have transformed clinical outcomes, including therapies aimed at HER2/neu, CDK4/6, PD-1/PD-L1, PARP, JAK2, and BTK. Moreover, innovative platforms such as antibody-drug conjugates (ADCs) have further revolutionized cancer treatment.  Other domains, such as neurodegeneration and metabolic diseases, have embraced targets like GLP-1, DPPIV, SGLT2, CGRP, BACE, and tau proteins. GLP-1 receptor agonists, in particular, are being explored not just in diabetes and obesity but also in cardiovascular and neuroinflammatory conditions, hinting at a paradigm shift in multi-indication targeting.

With the rise of mRNA technologies, long-acting injectables, and precision Nano-formulations, drug repurposing and lifecycle extension have gained momentum. Companies with proprietary formulation or delivery platforms often enter the spotlight following licensing agreements or strategic acquisitions by larger players—a testament to the growing value of enabling technologies. 

Emerging contaminants and residue management are now part of the drug development conversation. Multidisciplinary approaches are integrating pharmacokinetics, ecotoxicology, and real-world data to ensure safer, more sustainable therapeutics.

In our upcoming research reports, we plan to explore several of these advanced therapeutic targets and platform technologies. Whether you’re seeking insights into specific indications, drug classes, emerging biotech players, or regulatory trends, we’re happy to support customized projects tailored to your needs. Feel free to reach out for collaboration or bespoke analysis / any customized research on a therapy area/ drug/ company/ target.

“The greatest glory in living lies not in never falling, but in rising every time we fall.” — Nelson Mandela

Oct. 2018

Advance in Drug Delivery & Formulation Technology Series

Nanotherapeutics in the treatment of Cancer: Advances to Improve Efficacy, Bioavailability and Safety

Sept., 2018

Parkinson’s Disease

Molecular Landscape & Future Disease Modifying Targeted Therapies

May, 2018

Exploring Opportunities in Niche Therapies 

Human Cytomegalovirus (HCMV) Infections

Feb., 2018

Innovation in India Series

An Analysis of Select Pharma/Biotech Start-ups

Feb., 2018

Calcitonin – Gene Related Peptide (CGRP) Antagonists /Monoclonal Antibodies

New Targeted Therapies for Migraine

Nov., 2017

Myeloproliferative Neoplasms (MPN) and its overlaps with Myelodysplastic Syndromes (MDS)

Molecular Profiling and Treatment Dilemma – What, When, and How?

Sept., 2017

Oral Mucositis

An Analysis of Drugs in Development, Market Opportunity, unmet need, Disease prevalence and occurrence in cancer in Various Geographies

July, 2017

Poly(adenosine diphosphate [ADP]–ribose) Polymerases (PARPs) Inhibitors

Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential